CDK4/6 inhibitor biomarker research: are we barking up the wrong tree?
CDK4/6 inhibitors have emerged as a significant advance for the treatment of patients with advanced estrogen receptor positive (ER+) breast cancer. However, the identification of predictive markers that optimize their use is proving harder than expected. In this commentary we advocate for unbiased discovery and a collaborative approach across trials.